Metropolis Healthcare Ltd
Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 04 Aug 2026, 06:34 PM IST · BSE ID: d6b34987-d690-4323-8469-361047ffda53
View Original BSE Filing (PDF)
💡
In Simple Terms
Metropolis Healthcare announced its latest quarterly financial results, showing higher profits and revenues, but a business sale was delayed.
🤖 AI Summary
- Metropolis Healthcare's standalone net profit for Q1 FY27 was Rs. 505.83 million, up from Rs. 355.82 million year-over-year.
- Revenue from operations for the quarter ended June 30, 2026, stood at Rs. 3,722.84 million, compared to Rs. 3,232.69 million in the prior year period.
- Earnings per share (basic) from continuing and discontinuing operations was Rs. 2.44 for the June 2026 quarter, up from Rs. 1.73 in June 2025.
- The sale and transfer of the External Quality Assessment Services Business is now expected to take an additional two months to complete.
- The Board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (Q1 FY27)
3,722.84 millions
15.17%
Total Income (Q1 FY27)
3,774.70 millions
15.76%
Profit for the period (Q1 FY27)
505.83 millions
42.16%
Earnings per share (Basic) (Q1 FY27)
2.44 Rs.
41.39%
🏢 How This Affects the Company
Revenue from operations for the quarter increased by Rs. 490.15 million year-over-year, indicating growth in core pathology services. The delay in completing the transfer of the External Quality Assessment Services Business extends the operational period of this division under the current structure.
Profit for the period from continuing operations rose to Rs. 506.54 million from Rs. 353.59 million year-over-year, improving profitability. Total expenses also increased to Rs. 3,110.94 million from Rs. 2,786.64 million in the prior year.
The External Quality Assessment Services Business will remain with the company for an additional two months beyond the initially planned February 04, 2026, to August 04, 2026, timeframe, requiring continued operational management of this division.
The delay in completing the business transfer introduces a minor operational uncertainty regarding the timeline for the subsidiary, Metropolis Quality Solutions Private Limited, to fully assume the External Quality Assessment Services Business.
👥 What This Means For Shareholders
✅
Action Required
No specific action is required from shareholders based on this financial results and business transfer update.
👤
Who Is Affected
All existing shareholders are affected by the company's financial performance as reflected in the increased profit for the period and earnings per share of Rs. 2.44. The delay in business transfer is an operational update.
🔍
Management Signal
The management's decision to approve the financial results indicates a commitment to regular reporting. The delay in business transfer signals operational complexities in asset divestment.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 financial results — check revenue and profit growth sustainability.
Update on External Quality Assessment Services Business transfer — confirm completion by October 2026.
Any further operational updates or strategic announcements from the Board.
LOW RISK
The financial results show growth. The business transfer delay is minor and procedural.
💡 Investor Takeaway
Metropolis Healthcare reported a Q1 FY27 standalone net profit of Rs. 505.83 million, a 42.16% year-over-year increase. Revenue from operations for the quarter ended June 30, 2026, was Rs. 3,722.84 million, up 15.17% year-over-year. The transfer of the External Quality Assessment Services Business is delayed by two months.
⚖️ Strengths & Concerns
✅ Positives
- Profit for the period increased by 42.16% year-over-year, reaching Rs. 505.83 million for the quarter ended June 30, 2026.
- Revenue from operations grew by 15.17% year-over-year, reporting Rs. 3,722.84 million for the quarter ended June 30, 2026.
⚠️ Concerns
- Total expenses for the quarter ended June 30, 2026, increased to Rs. 3,110.94 million from Rs. 2,786.64 million in the prior year period.
- The sale and transfer of External Quality Assessment Services Business faced an additional two-month delay from its originally scheduled completion.
❓ Frequently Asked Questions
What was Metropolis Healthcare's standalone net profit for the quarter ended June 30, 2026?
Metropolis Healthcare reported a standalone net profit of Rs. 505.83 million for the quarter ended June 30, 2026.
What was Metropolis Healthcare's revenue from operations for Q1 FY27?
Revenue from operations for the quarter ended June 30, 2026, was Rs. 3,722.84 million.
What was the earnings per share (basic) for Metropolis Healthcare for the quarter ended June 30, 2026?
Earnings per share (basic) from continuing and discontinuing operations for the quarter ended June 30, 2026, was Rs. 2.44.
Was there any update on the External Quality Assessment Services Business transfer?
The sale and transfer of the External Quality Assessment Services Business is now expected to take an additional two months to complete beyond the original schedule.
Questions based on this BSE filing only. For information purposes.